Skip to content
Cultural Foundation
Author:
C4 Therapeutics, Inc.
C4 Therapeutics to Participate in Upcoming Conferences
May 20, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 12, 2026
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
April 9, 2026
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
March 25, 2026
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 9, 2026